2026-09-21 · Équipe éditoriale KeXinMaterials

21 CFR 211 cGMP + ICH Q10 + Validation pharmaceutique Famille Valise de protection Guide B2B

US 21 CFR 211 (Bonne Pratique Fabrication Actuelle produits pharmaceutiques finis), ICH Q10 (Système Qualité Pharmaceutique) et FDA Guidance Validation Procédé sont les trois principales régulations fabrication pharmaceutique US. Ci-dessous guide d’achat B2B 2026 couvrant portée, qualification équipement, IQ/OQ/PQ, éléments PQS, gestion changements et corrélation valise de protection.

Portée 21 CFR 211 cGMP

US 21 CFR Part 211 establishes the minimum current good manufacturing practice (cGMP) requirements for preparation of drug products for human use. Applicable to all US pharmaceutical manufacturers + import manufacturers per FDA.

21 CFR 211 scope: Drug products for human use manufactured in USA OR imported into USA. Excludes blood + blood components (covered by 21 CFR 606), biologicals (covered by 21 CFR 600 series).

Subpart A (General Provisions): Scope, definitions, equivalence to other standards. Equipment + utensils + containers + closures + control of components + drug product containers + closures.

Subpart B (Organization + Personnel): Qualified personnel, training, GMP training for all employees, hygiene, medical examinations, consultants.

Subpart C (Buildings + Facilities): Design + construction, lighting, ventilation, air filtration (HEPA), air classification (ISO 5 / 7 / 8), segregation of operations, sanitation, maintenance.

Subpart D (Equipment): Design + size + location + construction + cleaning + maintenance + sanitization + identification + use + logs. Equipment surfaces must not react with drug product.

Subpart E (Control of Components + Drug Product Containers + Closures): Receipt, identification, storage, sampling, testing, approval, rejection. Pharmaceutical-grade material certificates required.

Subpart F (Production + Process Controls): Written procedures, batch production records, in-process controls, sampling + testing, time limits, environmental controls, prevention of cross-contamination, reprocessing.

Subpart G (Packaging + Labeling Control): Materials, issuance, operations, inspection, labeling reconciliation.

Subpart H (Holding + Distribution): Warehousing procedures, distribution records, oldest stock first.

Subpart I (Laboratory Controls): Sampling plans, testing procedures, calibration, stability testing (per ICH Q1A), reserve samples, microbiological testing.

Subpart J (Records + Reports): Batch production records, laboratory records, distribution records, complaints, recall procedures.

Subpart K (Returned + Salvaged Drug Products): Returned goods handling, reprocessing procedures, salvage operations, destruction procedures.

B2B relevance: For B2B pharmaceutical equipment suppliers (including protective cases used in pharma manufacturing + packaging + distribution), 21 CFR 211 compliance is required when equipment touches product OR is in product environment.

B2B recommendation: For 2026 US FDA-bound B2B orders, target 21 CFR 211 Subpart D (Equipment) + Subpart I (Laboratory Controls) + Subpart J (Records): equipment qualification (IQ/OQ/PQ), material certificates (USP/EP), documentation, GMP-compatible cleaning, validation support.

ICH Q10 Système Qualité Pharmaceutique

ICH Q10 (Pharmaceutical Quality System) is the international guideline adopted by US FDA, EU EMA, Japan PMDA, and other major regulatory agencies. Provides comprehensive PQS framework throughout product lifecycle.

ICH Q10 scope: Pharmaceutical products for human use (chemical + biological + biotechnological). Applies throughout product lifecycle: pharmaceutical development, technology transfer, commercial manufacturing, product discontinuation.

ICH Q10 elements (4 main + 2 enablers): (1) Process Performance + Product Quality Monitoring System, (2) Corrective Action + Preventive Action (CAPA) System, (3) Change Management System, (4) Management Review. Enablers: (5) Knowledge Management, (6) Quality Risk Management (per ICH Q9).

Process Performance + Product Quality Monitoring: Real-time monitoring of process + product quality. Trend analysis, statistical process control (SPC), annual product review (APR), product quality review (PQR).

CAPA System: Corrective action for non-conformances + preventive action for potential issues. Root cause investigation, effectiveness check, documentation per 21 CFR 211 Subpart J.

Change Management System: Change control for process + equipment + material + specification + documentation changes. Impact assessment, approval, implementation, effectiveness verification.

Management Review: Periodic executive review of PQS performance. Inputs: APR results, CAPA effectiveness, change control results, complaints, recalls, audits, regulatory inspections. Output: improvement actions.

Knowledge Management: Capturing + sharing product + process knowledge throughout organization. Includes historical data, technical expertise, lessons learned, scientific publications.

Quality Risk Management per ICH Q9: Risk identification, analysis, evaluation, control, communication, review. Tools: FMEA (per ICH Q9 examples), HACCP, fault tree, cause-and-effect diagrams.

Enabler relationship: Knowledge Management feeds all PQS elements. Quality Risk Management enables decision-making across all elements.

ICH Q10 + ICH Q8 (Pharmaceutical Development) + ICH Q9 (Quality Risk Management) + ICH Q11 (Development + Manufacture of Drug Substances): The four ICH quality guidelines together cover modern pharmaceutical quality.

Pharmaceutical Quality System vs GMP: cGMP is regulatory baseline (must comply). ICH Q10 PQS is enhanced system (enables continuous improvement + innovation + lifecycle management).

B2B relevance: For B2B pharmaceutical equipment + service suppliers, supporting client PQS (process performance + monitoring + CAPA + change control + risk management) is increasingly expected.

B2B recommendation: For 2026 global pharma-bound B2B orders, target ICH Q10 PQS support: process data sharing, CAPA collaboration, change notification, knowledge transfer documentation, risk-based qualification.

FDA Guidance Validation Procédé

FDA Process Validation Guidance (2011) defines three-stage process validation: Stage 1 Process Design, Stage 2 Process Qualification (IQ/OQ/PQ), Stage 3 Continued Process Verification. Replaces older 1987 guidance.

FDA Process Validation scope: All pharmaceutical manufacturing processes. Required for finished pharmaceuticals (oral solid, sterile, biologic, etc.). Per 21 CFR 211.110(a)(2) and 21 CFR 211.220.

Stage 1 Process Design: Define commercial process based on development + scale-up data. Quality target product profile (QTPP), critical quality attributes (CQA), critical process parameters (CPP), risk assessment per ICH Q9. Output: validated recipe.

Stage 2 Process Qualification: (2a) IQ (Installation Qualification) - equipment installed per spec. (2b) OQ (Operational Qualification) - equipment operates at operating range. (2c) PQ (Performance Qualification) - process produces acceptable product under simulated commercial conditions.

IQ (Installation Qualification): Verify equipment + utilities + instrumentation installed per spec. Check manufacturer documentation, calibration, utility connections, environmental conditions, installation verification (welds, seals, alignment).

OQ (Operational Qualification): Verify equipment operates at defined operating range. Test upper + lower limits, alarms, interlocks, safety systems, fail-safe modes. Typically with placebo or simulated product (NOT commercial product).

PQ (Performance Qualification): Verify process produces acceptable product under commercial conditions. Multiple consecutive batches (typically 3-5) using commercial product + commercial formula. Confirms CQA + CPP relationship established in Stage 1.

Stage 3 Continued Process Verification: Ongoing verification during commercial manufacturing. Real-time monitoring, statistical process control (SPC), trend analysis, CAPA. Annual Product Review (APR) / Product Quality Review (PQR).

Equipment qualification vs process validation: IQ/OQ verify equipment works. PQ verifies process using equipment produces acceptable product. Equipment qualification is part of Stage 2 process qualification.

Validation documentation: Validation Master Plan (VMP), IQ protocol + report, OQ protocol + report, PQ protocol + report, validation summary report. Each signed by QA + Engineering + Manufacturing.

Re-validation: When change control identifies significant change OR when trending shows drift. Annual review of validation status recommended.

Computer System Validation (CSV): Per FDA 21 CFR Part 11 + GAMP 5. Computerized systems used in pharmaceutical manufacturing require validation. Includes configuration, security, audit trail, electronic signatures.

B2B relevance: For B2B pharmaceutical equipment suppliers, equipment IQ/OQ protocol templates + execution support + documentation are essential.

B2B recommendation: For 2026 US pharma-bound B2B orders, supply with: IQ/OQ protocol templates, FAT protocol + report, validation support engineer, SAT (Site Acceptance Test), spare parts list, calibration certificates, training records, GMP-compliant cleaning procedure.

Qualification équipement + validation

Equipment qualification (IQ/OQ) and process validation (PQ) are required for all pharmaceutical manufacturing equipment. Protective cases used in pharmaceutical manufacturing or packaging are part of the validation scope.

IQ (Installation Qualification) scope: Equipment + utilities + instrumentation + control systems + safety systems + installation verification + calibration + utility connections + installation drawings + as-built specifications.

OQ (Operational Qualification) scope: Operating range verification (min + max + nominal), alarm verification, interlock verification, safety system verification, fail-safe mode verification, cleaning verification, environmental verification.

PQ (Performance Qualification) scope: Use commercial process + commercial product to confirm equipment performance. Multiple batches (3-5 minimum). Statistical analysis (SPC, control charts). Trend analysis baseline.

Cleanroom compatibility: Equipment used in cleanroom environment must be cleanroom-compatible. Smooth surfaces, no particle shedding, no microbial harborage, HEPA-filtered exhaust (if heat-generating), ozone-friendly materials.

Material compatibility: Equipment surfaces must not react with drug product. USP <88> Class VI plastic testing, FDA food-grade stainless (304 / 316L), FDA-grade elastomers (EPDM, silicone, Viton).

Cleaning verification: Equipment must be cleanable to defined residue limits. Cleaning agent compatibility, rinse analysis (TOC, conductivity), swab recovery (TOC, HPLC), visual cleanliness.

Sterilization: For sterile product equipment, sterilization validation per FDA Guidance + USP <85> (sterility) + USP <161> (endotoxin). Steam (121°C 15 min), dry heat (160°C 2 hr), EtO, gamma radiation (25-50 kGy), hydrogen peroxide vapor (VHP).

Software validation: Computer systems per 21 CFR Part 11 + GAMP 5. Category 3 (configurable), Category 4 (configured), Category 5 (custom). Validation includes URS (User Requirements Spec), FS (Functional Spec), DS (Design Spec), test scripts (IQ/OQ/PQ).

Change control: Equipment changes (hardware, software, process, material) require change control per PQS. Impact assessment, re-validation scope, approval, documentation.

Calibration: Equipment calibration per ISO 17025 or equivalent. Annual calibration minimum. Critical instruments (temperature, pressure, flow, weight) calibrated more frequently.

Documentation: VMP (Validation Master Plan), individual protocols (IQ/OQ/PQ), reports, deviation handling, change control, calibration certificates, training records. All retained per 21 CFR 211 Subpart J.

B2B recommendation: For 2026 pharma equipment B2B orders, supply: VMP template, IQ/OQ/PQ protocol templates, FAT protocol + report, validation support scope ($5-15k/engineer), spare parts list, calibration certificates, training records, GMP cleaning procedure, change notification procedure.

Validation nettoyage + stérilisation

Cleaning validation and sterilization validation are critical for pharmaceutical equipment. Inner protective case for sterile products must be validated for cleaning + sterilization.

Cleaning validation scope: Removal of product residue, cleaning agent residue, microbial contamination, endotoxin (for sterile), particulate matter. Acceptance criteria per product + equipment.

Cleaning agent selection: Compatible with equipment material, low toxicity, easy to rinse, GMP-grade. Common: 70% IPA, sodium hydroxide (0.1-1%), sodium hypochlorite (100-1000 ppm), peracetic acid, hydrogen peroxide.

Residue limits: Acceptable Daily Intake (ADI) × equipment surface area / next batch size. Typically <10 ppm for product, <1 ppm for cleaning agent.

Sampling methods: Swab sampling (TOC, HPLC), rinse sampling (TOC, conductivity), placebo sampling (next batch product analysis).

TOC (Total Organic Content) analysis: USP <643> + EP 2.2.44. Non-specific organic carbon detection. Acceptance criteria per product.

HPLC analysis: Specific product + cleaning agent quantification. More specific than TOC. Used for higher-risk products.

Visual inspection: Equipment visually clean after cleaning. No visible residue, no discoloration, no staining.

Microbial limits: Total aerobic microbial count (TAMC) <10 CFU/100 cm² (USP <1112> Class 5 / ISO 5). Yeast + mold <1 CFU/100 cm². Specified per product + cleanroom grade.

Endotoxin limits: For injectable / sterile products, endotoxin <0.25 EU/mL (USP <85>) per dose. Equipment rinse must be endotoxin-free.

Sterilization methods: Steam (121°C 15 min, 132°C 3 min), dry heat (160°C 2 hr, 170°C 1 hr), EtO (typical cycle), gamma radiation (25-50 kGy), VHP (typical cycle).

Sterilization validation: Per ISO 11137 (radiation), ISO 11135 (EtO), ISO 17665 (steam). SAL (Sterility Assurance Level) 10⁻¶ for terminal sterilization.

Cleaning + sterilization validation documentation: Validation protocol + report, residue analysis, microbial + endotoxin data, statistical analysis, change control.

B2B recommendation: For 2026 pharma B2B orders, supply protective case with: cleaning procedure (validated), cleaning agent list (USP/EP grade), sterilization procedure (validated per USP/ISO), residue analysis data, microbial + endotoxin data, change control procedure.

Corrélation valise de protection

Protective cases used in pharmaceutical manufacturing + packaging + distribution must be GMP-compatible, cleanable, sterilizable (for sterile products), and validated per 21 CFR 211 + ICH Q10 + FDA Process Validation Guidance.

GMP compatibility: Inner case surfaces must be GMP-compatible. FDA-grade stainless (304 / 316L), FDA-grade plastic (USP Class VI per USP <88>), FDA-grade silicone / EPDM / Viton seals. No materials that react with drug product.

Cleanability: Smooth, non-porous surfaces, no crevices, no dead legs, no threaded areas in product zone. Designed for CIP (clean-in-place) or COP (clean-out-of-place) cleaning.

Sterilization: For sterile product contact, inner case must be sterilizable by SIP (Steam Sterilization in Place) or removable for sterilization. Steam (121°C 15 min), VHP, gamma radiation per USP <85>.

Cleanroom: Inner case must be cleanroom-compatible for ISO 5 / 7 / 8 environments. Low particle shedding, no microbial harborage, smooth surfaces, no fabric (synthetic materials only).

Material traceability: Full material traceability per FDA cGMP. Mill certificates (3.1 per EN 10204) for stainless, USP Class VI certificates for plastics, FDA food-grade certificates for elastomers.

Documentation: Material certificates, surface finish certificates (Ra), dimensional inspection, welding documentation (per ASME BPE if bio-pharma), FAT/SAT reports, IQ/OQ support documentation.

Change control: Any change to inner case material, design, or manufacturing process requires change control notification to client. Change per ICH Q10 PQS Change Management.

Validation support: Inner case manufacturer provides IQ/OQ support scope (FAT protocol, IQ/OQ templates, validation support engineer). Per client VMP requirements.

Cleaning + sterilization validation: Inner case supplier provides cleaning procedure (validated) + sterilization procedure (validated). Documented per USP <85> + USP <161>.

Quality agreement: Quality agreement between inner case manufacturer + pharmaceutical client. Defines responsibilities, change control, documentation, audits, complaint handling.

B2B relevance: For B2B pharma equipment suppliers, 21 CFR 211 + ICH Q10 + FDA Process Validation compliance is required for all equipment that touches product OR is in product environment.

B2B recommendation: For 2026 pharma B2B orders, supply protective case with: GMP-compatible materials (USP Class VI plastic, FDA-grade stainless), cleanroom-compatible design (smooth surfaces, no crevices), validated cleaning procedure, validated sterilization procedure (for sterile products), full material traceability, IQ/OQ protocol templates, validation support engineer ($5-15k/engineer), quality agreement scope, USP <88> biocompatibility data, USP <85> sterility data.

FAQ

Articles connexes

• EU GDP 2013/C 343/01 + WHO TRS 961 + ICH Q1A Chaîne du froid pharma
• ISO 13485 Dispositifs médicaux QMS
• API Spec Q1 + ASME BPVC + PED Équipements sous pression